GT Biopharma Appoints Former Pfizer Executive as Chief Medical Officer

GT Biopharma (OTCQB:OXISD) announced the appointment of Dr. Raymond Urbanski as their new chief medical officer.
As quoted in the press release:

Dr. Urbanski will oversee development of key products in GT Biopharma’s product pipeline, including its platform targeted immunotherapy BiKE and TriKE technologies as well as its newly acquired Central Nervous System pipeline.
Dr. Urbanski spent eight years with Pfizer and held several positions with the company, including Vice President/CMO of the Established Products Business Unit, senior medical director of oncology clinical R&D, senior medical director of breast cancer products and medical director of diversified products.
He brings extensive experience in developing and overseeing clinical studies, including phase 3b and phase 4 studies (including line extensions) for sunitinib (Sutent), exemestane (Aromasin), irinotecan (Camptosar), epirubicin (Ellence), axitinib, IGF1R inhibitor, and tremelimumab.

Click here to read the full press release.

Source: www.accesswire.com